MétaCan
Menu
Back to cohort

Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2

2025· article· en· W7127657130 on OpenAlexaff
R S Rosenson, D Gaudet, R A Hegele, C M Ballantyne, S J Nicholls, K Lucas, Jennifer Hellawell, R Fu, Ma'An Muhsin, N J Leeper, G F Watts

Bibliographic record

VenueEuropean Heart Journal · 2025
Typearticle
Languageen
FieldMedicine
TopicLipid metabolism and disorders
Canadian institutionsUniversité de Montréal
Fundersnot available
KeywordsHyperlipidemiaTriglyceridePlaceboLipoproteinCholesterolResidual riskAdverse effectHepatic lipase

Abstract

fetched live from OpenAlex

Abstract Background Despite effective LDL-C lowering treatments, patients with mixed hyperlipidemia remain at high ASCVD residual risk attributed to cholesterol transported by LDL and triglyceride (TG)-rich lipoproteins (TRLs). Angiopoietin-like protein 3 (ANGPTL3) regulates lipoprotein metabolism in both the exogenous and endogenous pathways by inhibiting lipoprotein lipase, endothelial lipase and cellular lipoprotein uptake. Naturally-occuring ANGPTL3 loss-of-function variant carriers have lower levels of LDL-C, non-HDL-C, and TGs and reduced ASCVD risk. Zodasiran, an investigational RNAi therapeutic, inhibits hepatic ANGPTL3 expression. Aim To report the long-term efficacy and safety of zodasiran in adults with mixed hyperlipidemia (fasting TG 2-5.64 mmol/L and LDL-C ≥1.8-mmol/L or non-HDL-C ≥2.59-mmol/L. Methods 156 patients entering the OLE, of 204 originally randomized 3:1 to zodasiran 50/100/200mg or placebo subcutaneously on Day1 and Week12, received zodasiran 200mg quarterly during the extension period. Results Zodasiran reduced ANGPTL3, TG, non-HDL-C, apoB, and Remnant-cholesterol from baseline in a dose-dependent manner compared with placebo. By Month1 of the OLE, % change from baseline of TG attained levels were comparable to those in the main study, including among subjects previously on placebo. Durable and sustained reductions in mean % (SD) levels from baseline were -57.9% (22.9) for ANGPTL3; -55.9% (16.3) for TG, -30.1% (21.6) for non-HDL-C, -61.8% (21.2) for Remnant-cholesterol, -9.9% (30.6) for LDL-C, -15.8% (20.8) for apoB, -28.5% (17.9) for total cholesterol, and -19.9% (22.4) for HDL-C occurred in the extension from 1-month post-dose through 24 months. TEAEs occurred in 77.8%; serious AEs were reported in 13.5% of patients; 3.2% discontinued due to an AE. The most common AEs were COVID-19, upper respiratory tract infection, urinary tract infection, headache, Type 2 Diabetes Mellitus, sinusitis, and arthralgia. Conclusions Zodasiran delivered substantial and sustained reductions in ANGPTL3, TG, and atherogenic lipoproteins in patients with mixed hyperlipidemia, with a favorable safety profile, consistent with observations from the blinded portion of the study. The cardiovascular effects remain to be determined.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.314
Teacher spread0.273 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart JournalSame topicLipid metabolism and disordersFrench-language works237,207